Guggenheim Capital LLC Ultragenyx Pharmaceutical Inc. Transaction History

Guggenheim Capital LLC

  • $10.6 Billion
  • Q1 2025

A detailed history of Guggenheim Capital LLC transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Guggenheim Capital LLC holds 46,660 shares of RARE stock, worth $1.69 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
46,660
Previous 45,222 3.18%
Holding current value
$1.69 Million
Previous $1.9 Million 11.2%
% of portfolio
0.02%
Previous 0.02%

Shares

31 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 14, 2025
BUY
$36.21 - $45.78 $52,069 - $65,831
1,438 Added 3.18%
46,660 $1.69 Million
Q4 2024

Feb 13, 2025
BUY
$42.07 - $57.72 $28,186 - $38,672
670 Added 1.5%
45,222 $1.9 Million
Q3 2024

Nov 13, 2024
BUY
$40.21 - $59.36 $159,070 - $234,828
3,956 Added 9.74%
44,552 $2.47 Million
Q2 2024

Aug 14, 2024
BUY
$37.42 - $51.61 $175,911 - $242,618
4,701 Added 13.1%
40,596 $1.67 Million
Q1 2024

May 14, 2024
BUY
$43.02 - $53.69 $352,161 - $439,506
8,186 Added 29.54%
35,895 $1.68 Million
Q4 2023

Feb 14, 2024
BUY
$31.73 - $49.19 $61,936 - $96,018
1,952 Added 7.58%
27,709 $1.33 Million
Q3 2023

Nov 14, 2023
BUY
$34.92 - $46.66 $216,748 - $289,618
6,207 Added 31.75%
25,757 $918,000
Q2 2023

Aug 11, 2023
SELL
$37.35 - $52.15 $136,476 - $190,556
-3,654 Reduced 15.75%
19,550 $901,000
Q1 2023

May 10, 2023
SELL
$36.99 - $48.71 $279,126 - $367,565
-7,546 Reduced 24.54%
23,204 $930,000
Q4 2022

Feb 14, 2023
BUY
$33.72 - $46.33 $14,870 - $20,431
441 Added 1.46%
30,750 $1.42 Million
Q3 2022

Nov 14, 2022
SELL
$39.96 - $66.14 $3,596 - $5,952
-90 Reduced 0.3%
30,309 $1.26 Million
Q2 2022

Aug 15, 2022
BUY
$45.8 - $85.4 $64,806 - $120,841
1,415 Added 4.88%
30,399 $1.81 Million
Q1 2022

May 16, 2022
BUY
$62.2 - $84.4 $90,812 - $123,224
1,460 Added 5.3%
28,984 $2.1 Million
Q4 2021

Feb 14, 2022
BUY
$73.71 - $87.86 $209,704 - $249,961
2,845 Added 11.53%
27,524 $2.32 Million
Q3 2021

Nov 15, 2021
SELL
$77.92 - $102.4 $8,493 - $11,161
-109 Reduced 0.44%
24,679 $2.23 Million
Q2 2021

Aug 13, 2021
BUY
$92.19 - $115.71 $234,439 - $294,250
2,543 Added 11.43%
24,788 $2.36 Million
Q1 2021

May 13, 2021
BUY
$106.9 - $167.73 $413,275 - $648,444
3,866 Added 21.03%
22,245 $2.53 Million
Q4 2020

Feb 16, 2021
SELL
$84.4 - $177.39 $1.14 Million - $2.39 Million
-13,486 Reduced 42.32%
18,379 $2.54 Million
Q3 2020

Nov 13, 2020
SELL
$72.98 - $90.0 $702,651 - $866,520
-9,628 Reduced 23.2%
31,865 $2.62 Million
Q2 2020

Aug 14, 2020
SELL
$46.91 - $78.22 $333,436 - $555,987
-7,108 Reduced 14.63%
41,493 $3.25 Million
Q1 2020

Jun 02, 2020
SELL
$33.8 - $62.9 $322,418 - $600,003
-9,539 Reduced 16.41%
48,601 $2.16 Million
Q4 2019

Feb 14, 2020
BUY
$36.08 - $45.83 $385,045 - $489,097
10,672 Added 22.48%
58,140 $2.48 Million
Q3 2019

Nov 14, 2019
BUY
$42.5 - $63.11 $163,157 - $242,279
3,839 Added 8.8%
47,468 $2.03 Million
Q2 2019

Aug 14, 2019
SELL
$54.93 - $74.36 $126,119 - $170,730
-2,296 Reduced 5.0%
43,629 $2.77 Million
Q1 2019

May 15, 2019
SELL
$39.87 - $69.36 $138,588 - $241,095
-3,476 Reduced 7.04%
45,925 $3.19 Million
Q4 2018

Feb 14, 2019
BUY
$38.89 - $77.3 $142,959 - $284,154
3,676 Added 8.04%
49,401 $2.15 Million
Q3 2018

Nov 14, 2018
SELL
$71.81 - $90.15 $115,255 - $144,690
-1,605 Reduced 3.39%
45,725 $3.49 Million
Q2 2018

Aug 14, 2018
SELL
$48.54 - $85.31 $500,787 - $880,143
-10,317 Reduced 17.9%
47,330 $3.64 Million
Q1 2018

May 15, 2018
BUY
$44.33 - $58.52 $24,159 - $31,893
545 Added 0.95%
57,647 $2.94 Million
Q4 2017

Feb 14, 2018
SELL
$43.54 - $57.32 $517,777 - $681,649
-11,892 Reduced 17.24%
57,102 $2.65 Million
Q3 2017

Nov 14, 2017
BUY
$49.79 - $66.32 $3.44 Million - $4.58 Million
68,994
68,994 $3.68 Million

Others Institutions Holding RARE

# of Institutions
335
Shares Held
88.9M
Call Options Held
1.08M
Put Options Held
1.04M
View Full List

About Ultragenyx Pharmaceutical Inc.

RARE Quotes by TradingView
  • Ticker RARE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,036,896
  • Market Cap $2.53B
  • Description
  • Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...
More about RARE
Track This Portfolio

Track Guggenheim Capital LLC Portfolio

Follow Guggenheim Capital LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Guggenheim Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Guggenheim Capital LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email